Comparison of Pain After Uterine Artery Embolization Using Gelatin Microsphere or Tris-acryl Gelatin Microsphere
Primary Purpose
Uterine Myoma, Uterine Fibroid
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Gelatin microsphere (Nexsphere™)
Embosphere
Sponsored by
About this trial
This is an interventional treatment trial for Uterine Myoma
Eligibility Criteria
Inclusion Criteria:
- A patient aged between 20 and under 60 who decided to undergo uterine artery embolization for symptomatic uterine myoma.
Exclusion Criteria:
- Bradycardia on electrocardiogram (< 45 bpm)
- Ventricular conduction abnormalities
- Liver failure
- Kidney failure
- Uncontrolled high blood pressure
- Obesity (BMI ≥ 30 ㎏/㎡)
- Patients who are allergic to drugs
- Patients who cannot read consent forms such as illiterate or foreigners
- Pregnant woman
Sites / Locations
- Severance Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Test group
Control group
Arm Description
The test group will be administered 300-500 ㎛ range of Gelatin microsphere (Nexsphere™). A suspension in which a contrast medium and physiological saline are mixed will be administered until the embolization is sufficiently achieved.
The control group will be administered 500-700 ㎛ of Embospheres until sufficient embolization is achieved.
Outcomes
Primary Outcome Measures
Pain intensity by numerical rating scale
0-10 numerical rating scale (0, no pain at all; 10, worst pain imaginable
Secondary Outcome Measures
Fentanyl and analgesic usage volume
Fentanyl and analgesic usage volume within 24 hours after embolization
Symptom severity score
Comparison of symptom severity score before and 3 months after embolization
Symptom was scored on a scale of 0-10, with 0 being no symptoms and 10 being the baseline, or initial symptoms.
Postoperative inflammation
Comparison of level or counts of C-Reactive Protein (CRP), leukocyte, neutrophil before and after embolization
Tumor necrosis degree
Assessment of tumor necrosis degree in MR after embolization
Fluoroscopy and procedure time
Fluoroscopy and procedure time taken for embolization to achieved
Serum Anti-Mullerian Hormone (AMH)
Residual ovarian function before and after embolization
Full Information
NCT ID
NCT05086770
First Posted
September 28, 2021
Last Updated
July 12, 2023
Sponsor
Next Biomedical Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT05086770
Brief Title
Comparison of Pain After Uterine Artery Embolization Using Gelatin Microsphere or Tris-acryl Gelatin Microsphere
Official Title
Comparison of Pain After Uterine Artery Embolization Using Gelatin Microsphere or Tris-acryl Gelatin Microsphere in Patients With Symptomatic Fibroids: A Prospective, Randomized Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
May 31, 2021 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
November 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Next Biomedical Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is a prospective and randomized investigation planned to compare pain after uterine artery embolization using Gelatin microsphere or tris-acryl gelatin microsphere in 60 patients with symptomatic fibroids.
Detailed Description
This investigational study is designed to compare pain after uterine artery embolization using Gelatin microsphere or tris-acryl gelatin microsphere in patients with symptomatic fibroids.
The primary end-points will be evaluated by assessing the maximum Visual Analogue Scale (VAS) score obtained for each time points within 24 hours after embolization.
Secondary end-points consist of evaluating six items: 1) fentanyl and analgesic usage within 24 hours, 2) comparison of symptom severity score and health-related quality of life score, 3) comparison of postoperative inflammation, 4) assessment of tumor necrosis degree in Magnetic Resonance Imaging, 5) fluoroscopy and procedure time comparison, and 6) assessment of residual ovarian function before and after surgery (Serum AMH).
This study included patients between the ages of 20 and less than 60 years of age who were diagnosed with uterine myoma and planned to undergo uterine artery embolization.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterine Myoma, Uterine Fibroid
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Test group
Arm Type
Experimental
Arm Description
The test group will be administered 300-500 ㎛ range of Gelatin microsphere (Nexsphere™). A suspension in which a contrast medium and physiological saline are mixed will be administered until the embolization is sufficiently achieved.
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
The control group will be administered 500-700 ㎛ of Embospheres until sufficient embolization is achieved.
Intervention Type
Device
Intervention Name(s)
Gelatin microsphere (Nexsphere™)
Intervention Description
Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
Intervention Type
Device
Intervention Name(s)
Embosphere
Intervention Description
Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
Primary Outcome Measure Information:
Title
Pain intensity by numerical rating scale
Description
0-10 numerical rating scale (0, no pain at all; 10, worst pain imaginable
Time Frame
0-24 hours after embolization
Secondary Outcome Measure Information:
Title
Fentanyl and analgesic usage volume
Description
Fentanyl and analgesic usage volume within 24 hours after embolization
Time Frame
24 hours
Title
Symptom severity score
Description
Comparison of symptom severity score before and 3 months after embolization
Symptom was scored on a scale of 0-10, with 0 being no symptoms and 10 being the baseline, or initial symptoms.
Time Frame
3 months
Title
Postoperative inflammation
Description
Comparison of level or counts of C-Reactive Protein (CRP), leukocyte, neutrophil before and after embolization
Time Frame
24 hours
Title
Tumor necrosis degree
Description
Assessment of tumor necrosis degree in MR after embolization
Time Frame
3 months
Title
Fluoroscopy and procedure time
Description
Fluoroscopy and procedure time taken for embolization to achieved
Time Frame
procedure time
Title
Serum Anti-Mullerian Hormone (AMH)
Description
Residual ovarian function before and after embolization
Time Frame
3 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
59 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
A patient aged between 20 and under 60 who decided to undergo uterine artery embolization for symptomatic uterine myoma.
Exclusion Criteria:
Bradycardia on electrocardiogram (< 45 bpm)
Ventricular conduction abnormalities
Liver failure
Kidney failure
Uncontrolled high blood pressure
Obesity (BMI ≥ 30 ㎏/㎡)
Patients who are allergic to drugs
Patients who cannot read consent forms such as illiterate or foreigners
Pregnant woman
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Man Deuk Kim, MD, PhD
Organizational Affiliation
Severance Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Severance Hospital
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Comparison of Pain After Uterine Artery Embolization Using Gelatin Microsphere or Tris-acryl Gelatin Microsphere
We'll reach out to this number within 24 hrs